-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 13, China Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary General Sanyo received a "drug registration certificate" for vildagliptin tablets approved and issued by the State Drug Administration for the treatment of type 2 diabetes
On September 20, 2019, General Sanyo submitted the drug registration application to the State Food and Drug Administration and was accepted
The drug was developed by Novartis and applied for marketing in the EU for the first time on September 26, 2007, with a specification of 50 mg and a trade name of Galvus®; at present, vildagliptin tablets have been approved for import and marketing in China
The drug is suitable for the treatment of type 2 diabetes
According to the data query on the website of the State Food and Drug Administration, up to now, the drug is owned by Qilu Pharmaceutical Co.
As of the disclosure date of this announcement, GM Sanyo has invested approximately RMB 17 million in the drug R&D project (unaudited)
According to the PDB database sample hospital drug sales statistics, the total sales amount of the drug sample hospital in 2020 is about 90 million yuan
